393 related articles for article (PubMed ID: 25287991)
21. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
[TBL] [Abstract][Full Text] [Related]
22.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
23. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation.
Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A
Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893
[TBL] [Abstract][Full Text] [Related]
24. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.
Kantorova B; Malcikova J; Brazdilova K; Borsky M; Plevova K; Smardova J; Radova L; Tom N; Trbusek M; Diviskova E; Francova HS; Navrkalova V; Doubek M; Brychtova Y; Mayer J; Pospisilova S
Br J Haematol; 2017 Sep; 178(6):979-982. PubMed ID: 27470445
[No Abstract] [Full Text] [Related]
25. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
[TBL] [Abstract][Full Text] [Related]
27. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.
Minervini CF; Cumbo C; Orsini P; Brunetti C; Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Impera L; Giordano A; Specchia G; Albano F
Diagn Pathol; 2016 Oct; 11(1):96. PubMed ID: 27724982
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
29. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
30. Genetic evolution in chronic lymphocytic leukaemia.
Delgado J; Villamor N; López-Guillermo A; Campo E
Best Pract Res Clin Haematol; 2016 Mar; 29(1):67-78. PubMed ID: 27742073
[TBL] [Abstract][Full Text] [Related]
31. Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
Olbertova H; Plevova K; Pavlova S; Malcikova J; Kotaskova J; Stranska K; Spunarova M; Trbusek M; Navrkalova V; Dvorackova B; Tom N; Pal K; Jarosova M; Brychtova Y; Panovska A; Doubek M; Pospisilova S
BMC Cancer; 2022 Feb; 22(1):137. PubMed ID: 35114947
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
33. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leeksma AC; Taylor J; Wu B; Gardner JR; He J; Nahas M; Gonen M; Alemayehu WG; Te Raa D; Walther T; Hüllein J; Dietrich S; Claus R; de Boer F; de Heer K; Dubois J; Dampmann M; Dürig J; van Oers MHJ; Geisler CH; Eldering E; Levine RL; Miller V; Mughal T; Lamanna N; Frattini MG; Heaney ML; Zelenetz A; Zenz T; Abdel-Wahab O; Kater AP
Leukemia; 2019 Feb; 33(2):390-402. PubMed ID: 30038380
[TBL] [Abstract][Full Text] [Related]
34. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
35. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
37. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
Sutton LA; Rosenquist R
Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442
[TBL] [Abstract][Full Text] [Related]
38. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
39. Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia.
Pinto AM; Papa FT; Frullanti E; Meloni I; Tita R; Caselli R; Fallerini C; Lopergolo D; Cetta F; Mencarelli MA; Bocchia M; Gozzetti A; Renieri A
Br J Haematol; 2019 Feb; 184(4):657-659. PubMed ID: 29460960
[No Abstract] [Full Text] [Related]
40. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
